Splanchnic Venous Capacitance in Postural Tachycardia Syndrome
NCT05375968 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 50
Last updated 2025-12-05
Summary
Postural tachycardia syndrome (POTS) affects ≈3 million young people, characterized by chronic presyncopal symptoms characterized by dizziness, lightheadedness, and orthostatic tachycardia that occur while standing. Across-sectional survey found that 25% of these patients complains that meals rich in carbohydrates are among the factors that further exacerbate POTS's symptoms and cause a myriad of gastrointestinal symptoms.
The splanchnic circulation is the largest blood volume reservoir of the human body, storing ≈25% of the total blood volume and contributing to sudden, and large, fluctuations in the stroke volume (SV). The orthostatic changes in systemic hemodynamics are particularly magnified after meals, due to increased blood volume sequestration triggered by the release of gastrointestinal peptides with vasodilatory properties. The purpose of this study is to determine if the worsening orthostatic tachycardia and symptoms after glucose ingestion in POTS patients are due to a greater increase in splanchnic venous capacitance and excessive blood pooling on standing as compare to Healthy controls.
The study will also determine if glucose-induced GIP secretion increases splanchnic venous capacitance, orthostatic tachycardia and worsening POTS postprandial symptoms. For this purpose subjects will be further randomized to either saline versus GIP(3-30)NH2 acute infusion, to measure the changes their splanchnic venous capacitance and superior mesenteric arterial flow before and after a 75-g oral glucose challenge during supine and 45-degree head-up tilt positions (orthostatic challenge) for up to 3 hours.
Conditions
- Postural Tachycardia Syndrome (POTS)
Interventions
- DIAGNOSTIC_TEST
-
Measurement of Splanchnic venous capacitance(SVC)done at Baseline and after 90 min of 75 g glucose in Healthy Controls POTS patients
While segmental bioimpedance is monitored, continuous positive airway pressure (CPAP) will be applied sequentially at 0, 4, 8, 12, and 16 cm H2O for about 30 seconds each. This positive airway pressure will increase the intrathoracic pressure, which is transmitted to the venous circulation. Pressure (CPAP pressure, X axis) - volume (splanchnic vascular volume measured by segmental impedance and expressed as % change from baseline, Y axis) relationships are then constructed to assess for splanchnic venous capacitance
- DIAGNOSTIC_TEST
-
Measurement of Splanchnic venous capacitance(SVC)done at Baseline and after 90 min of 75 g glucose in Healthy Controls
While segmental bioimpedance is monitored, continuous positive airway pressure (CPAP) will be applied sequentially at 0, 4, 8, 12, and 16 cm H2O for about 30 seconds each. This positive airway pressure will increase the intrathoracic pressure, which is transmitted to the venous circulation. Pressure (CPAP pressure, X axis) - volume (splanchnic vascular volume measured by segmental impedance and expressed as % change from baseline, Y axis) relationships are then constructed to assess for splanchnic venous capacitance
- DRUG
-
Compare change is SVC and SMA flow due to GIP antagonist GIP(3-30)NH2
Participants with POTS will be randomize to either saline versus GIP(3-30)NH2 acute infusion. We will measure changes in their splanchnic venous capacitance and superior mesenteric arterial flow before and after a 75-g oral glucose challenge during supine and 45-degree head-up tilt positions (orthostatic challenge) for up to 3 hr. Notably, we will assess changes in venous capacitance using segmental impedance to measure the effect of graded positive airway pressure (CPAP) on splanchnic blood volume.
- DRUG
-
Compare change is SVC and SMA flow due to saline
Participants with POTS will be randomize to either saline versus GIP(3-30)NH2 acute infusion. We will measure changes in their splanchnic venous capacitance and superior mesenteric arterial flow before and after a 75-g oral glucose challenge during supine and 45-degree head-up tilt positions (orthostatic challenge) for up to 3 hr. Notably, we will assess changes in venous capacitance using segmental impedance to measure the effect of graded positive airway pressure (CPAP) on splanchnic blood volume.
Sponsors & Collaborators
-
National Heart, Lung, and Blood Institute (NHLBI)
collaborator NIH -
Vanderbilt University Medical Center
lead OTHER
Principal Investigators
-
Cyndya Shibao, M.D · Vanderbilt University Medical Center
Study Design
- Allocation
- RANDOMIZED
- Purpose
- DIAGNOSTIC
- Masking
- DOUBLE
- Model
- CROSSOVER
Eligibility
- Min Age
- 18 Years
- Max Age
- 50 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2023-02-25
- Primary Completion
- 2027-05-31
- Completion
- 2028-06-01
- FDA Drug
- Yes
- FDA Device
- Yes
Countries
- United States
Study Locations
More Related Trials
-
Evaluating the Prevalence of Acute Hepatic Porphyria in Postural Tachycardia Syndrome
NCT05344599 ·Status: ACTIVE_NOT_RECRUITING
-
Early Use of Vasopressin in Post-Fontan Management
NCT03088345 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
CRI in POTS in Adolescents
NCT03974737 ·Status: COMPLETED
-
Enhanced External Counterpulsation in Patients With Fontan Circulation
NCT04956952 ·Status: COMPLETED ·Phase: NA
-
Head Circumference Growth in Children With Ehlers-Danlos Syndrome Who Develop Dysautonomia Later in Life
NCT01367977 ·Status: COMPLETED
-
To Assess the Efficacy of Midodrine in Prevention of Cirrhosis Related Complications in Children Awaiting Liver Transplantation.
NCT05287100 ·Status: COMPLETED ·Phase: NA
-
Comparison of Continuous Non-Invasive and Invasive Intracranial Pressure Measurement
NCT01863381 ·Status: TERMINATED ·Phase: NA
-
Qualitative Sweat Distribution During Tilt Table Procedure
NCT02329548 ·Status: COMPLETED ·Phase: NA
-
Evaluation of the Safety and Effectiveness of the CereVasc® eShunt® System in Normal Pressure Hydrocephalus
NCT06498960 ·Status: RECRUITING ·Phase: NA
-
Impact of the Administration of Fludrocortisone in Very Premature Infants
NCT03001089 ·Status: COMPLETED ·Phase: PHASE2
-
Use of Vasopressin Following the Fontan Operation
NCT02975999 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
PRecIsion Medicine in CardiomyopathY
NCT04036799 ·Status: ACTIVE_NOT_RECRUITING
-
Nesiritide Use Following Cardiac Surgery in Infants
NCT00281671 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
Effect of Domperidone on QT Interval in Premature Infants
NCT00238056 ·Status: COMPLETED ·Phase: PHASE2
-
Electrocardiograph Changes and Holter Abnormalities in Children With Predialytic Chronic Kidney Disease
NCT05726071 ·Status: UNKNOWN
-
The Role of Susceptibility to Thrombosis in the Pseudotumor Cerebri of Nephropathic Cystinosis: A Case-Control Study
NCT00071903 ·Status: COMPLETED
-
Study of Energy Expenditure in Infants With Ventricular Septal Defects
NCT00006272 ·Status: UNKNOWN
-
Urine Levels of Metanephrin and Normetanephrin in Patients With Frequent Ventricular Premature Complex
NCT03447002 ·Status: COMPLETED
-
Heart Rate Variability in Children With a Functional Gastrointestinal Disorder
NCT00195975 ·Status: COMPLETED
-
Volumetrics and Proteomics in Shunted Normal Pressure Hydrocephalus
NCT04785560 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA
-
The Pharmacology and Hemodynamics of Dexmedetomidine in Children With Congenital Heart Disease
NCT00480740 ·Status: COMPLETED ·Phase: PHASE3
-
Anterior Pituitary Function in Patients With Hydrocephalus
NCT00149721 ·Status: TERMINATED ·Phase: NA
-
Cerebral Anatomy, Hemodynamics and Metabolism
NCT02919956 ·Status: COMPLETED
-
Assessment of ShuntCheck Performance Characteristics in Asymptomatic Patients With Normal Pressure Hydrocephalus
NCT04011566 ·Status: RECRUITING
-
The Role of the Glymphatic System Avaluated Thourgh mr Imaging in the Diagnosis and Management of NPH
NCT06857136 ·Status: COMPLETED